Abeona director plans sale of 15,000 shares

Rhea-AI Filing Summary

ABEONA THERAPEUTICS INC. (ABEO) director Mark Alvino has filed a notice to sell common stock under Rule 144. The planned sale covers 15,000 shares of common stock through broker Stifel Nicolaus & Company Inc., with an aggregate market value of $87,966.00, and is listed for 09/01/2026 on Nasdaq. The shares relate to Restricted Stock Awards granted as equity compensation on 08/26/2025 (1,614 shares) and 01/31/2026 (13,386 shares).

Key Figures

Shares to be sold: 15,000 shares of common stock Aggregate market value: $87,966.00 Restricted Stock Award 1: 1,614 shares +2 more

5 metrics

Shares to be sold 15,000 shares of common stock Planned Rule 144 sale by director Mark Alvino through Stifel Nicolaus & Company Inc.

Aggregate market value $87,966.00 Total market value of 15,000 ABEO shares listed for sale on 09/01/2026

Restricted Stock Award 1 1,614 shares Equity compensation dated 08/26/2025 from issuer

Restricted Stock Award 2 13,386 shares Equity compensation dated 01/31/2026 from issuer

Planned sale date 09/01/2026 Date associated with the Rule 144 sale of 15,000 ABEO shares on Nasdaq

Key Terms

Rule 144, Restricted Stock Awards, Equity Compensation

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Awards financial

"Common Stock | 08/26/2025 | Restricted Stock Awards | Issuer"

Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.

Equity Compensation financial

"1614 | 08/26/2025 | Equity Compensation"

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

FAQ

What insider sale is being reported for ABEO in this Form 144?

Director Mark Alvino filed to sell 15,000 shares of Abeona Therapeutics Inc. common stock under Rule 144. The sale is to be executed through Stifel Nicolaus & Company Inc. with an aggregate market value of $87,966.00, and is listed for 09/01/2026 on Nasdaq.

What is the total market value of ABEO shares covered by this Form 144?

The Form 144 reports an aggregate market value of $87,966.00 for the planned sale of 15,000 Abeona Therapeutics Inc. common shares by director Mark Alvino, to be executed through Stifel Nicolaus & Company Inc. and listed for 09/01/2026 on Nasdaq.

What is the source of the ABEO shares to be sold by Mark Alvino?

The 15,000 Abeona Therapeutics Inc. shares come from Restricted Stock Awards issued by the issuer as equity compensation, consisting of 1,614 shares dated 08/26/2025 and 13,386 shares dated 01/31/2026.

Which broker is handling the planned ABEO share sale under this Form 144?

The planned sale of 15,000 Abeona Therapeutics Inc. common shares by director Mark Alvino will be handled by Stifel Nicolaus & Company Inc., with the shares listed for trading on Nasdaq on 09/01/2026.

What type of securities are being sold in this ABEO Form 144 filing?

The securities are common stock of Abeona Therapeutics Inc., totaling 15,000 shares. They arise from Restricted Stock Awards granted as equity compensation by the issuer on 08/26/2025 and 01/31/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 04:06 PM Accepted by SEC EDGAR 09/01/2026 - 04:05 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001356828
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ABEONA THERAPEUTICS INC.
SEC File Number	001-15771
Address of Issuer	6555 CARNEGIE AVE, 4TH FLOOR CLEVELAND OHIO 44103
Phone	646-813-4701
Name of Person for Whose Account the Securities are To Be Sold	Alvino Mark
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Stifel Nicolaus & Company Inc 501 N Broadway St. Louis MO 63102	15000	87966.00	57184017	09/01/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	08/26/2025	Restricted Stock Awards	Issuer			1614	08/26/2025	Equity Compensation
Common Stock	01/31/2026	Restricted Stock Awards	Issuer			13386	01/31/2026	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/01/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ James Weimer, as a duly authorized representative of STIFEL, as attorney-in-fact for Mark Alvino
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)